# US 2006/0040855 A1 · Low efficacy gonadotropin agonists and antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040855 A1
- Document ID: US20060040855A1
- Status: Published application
- Kind: A1
- Application number: 11/152,601
- Filed: 2005-06-14
- Published: 2006-02-23
- Earliest claimed: 2004-01-08
- Inventors: William Moyle
- Web page: https://patentgrep.com/patent/US20060040855A1

## CPC

- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides glycoprotein hormone analogs having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide. The analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond. The present invention also provides a method for stimulating fertility in mammals by promoting apoptosis of ovarian cells and/or luteal cells, which comprises administering to the mammal a therapeutically effective amount of a glycoprotein hormone analog having partial agonist/antagonist activity.

## Claims

### Claim 1

A glycoprotein hormone analog having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide, wherein the analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond.

### Claim 2 (depends on 1)

The analog according to claim 1, wherein the disulfide bond is between α-subunit residue 37 and β-subunit residue 33.

### Claim 3 (depends on 2)

The analog according to claim 2, wherein the analog is dgα37-β33CF or dgα37-β33CRF.

### Claim 4 (depends on 1)

The analog according to claim 1, wherein the disulfide bond is between α-subunit residue 35 and β-subunit residue 35.

### Claim 5 (depends on 4)

The analog according to claim 4, wherein the analog is dgα35-β35CF or dgα35-β35CRF.

### Claim 6 (depends on 2)

The analog according to claim 2, wherein the analog contains hCG β-subunit residues 101-109.

### Claim 7 (depends on 6)

The analog according to claim 6, wherein FSH β-subunit residues 95-103 are substituted for the hCG β-subunit residues 101-109.

### Claim 8 (depends on 4)

The analog according to claim 4, wherein the analog contains hCG β-subunit residues 101-109.

### Claim 9 (depends on 8)

The analog according to claim 8, wherein FSH β-subunit residues 95-103 are substituted for the hCG β-subunit residues 101-109.

### Claim 10 (depends on 2)

The analog according to claim 2, wherein the α-subunit is fused to the end of the β-subunit to form a single chain analog.

### Claim 11 (depends on 4)

The analog according to claim 4, wherein the α-subunit is fused to the end of the β-subunit to form a single chain analog.

### Claim 12 (depends on 1)

The analog according to claim 1, wherein the analog is a fusion protein comprising a toxic agent, which agent is toxic to gonadotropin receptor bearing cells.

### Claim 13 (depends on 12)

The analog according to claim 12, wherein the toxic agent is selected from the group consisting of β-lactamase, γ-interferon, Fas ligand, sphingomyelinase, apoptosis promoting agents, proteases, phospholipases, and steroidogenesis inhibiting agents.

### Claim 14 (depends on 1)

The analog according to claim 1, wherein an oligosaccharide in the analog is tethered to a toxic agent, which agent is toxic to gonadotropin receptor bearing cells.

### Claim 15

A method for stimulating fertility in mammals by promoting apoptosis of ovarian cells which comprises administering to the mammal a therapeutically effective amount of a glycoprotein hormone analog having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide, wherein the analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the disulfide bond is between α-subunit residue 37 and β-subunit residue 33.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the analog is dgα37-β33CF or dgα37-β33CRF.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the disulfide bond is between α-subunit residue 35 and β-subunit residue 35.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the analog is dgα35-β35CF or dgα35-β35CRF.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the analog contains hCG β-subunit residues 101-109.

### Claim 21 (depends on 20)

The method according to claim 20, wherein FSH β-subunit residues 95-103 are substituted for the hCG β-subunit residues 101-109.

### Claim 22 (depends on 18)

The method according to claim 18, wherein the analog contains hCG β-subunit residues 101-109.

### Claim 23 (depends on 20)

The method according to claim 20, wherein FSH β-subunit residues 95-103 are substituted for the hCG β-subunit residues 101-109.

### Claim 24 (depends on 16)

The method according to claim 16, wherein the α-subunit is fused to the end of the β-subunit to form a single chain analog.

### Claim 25 (depends on 18)

The method according to claim 18, wherein the α-subunit is fused to the end of the β-subunit to form a single chain analog.

### Claim 26 (depends on 15)

The method according to claim 15, wherein the analog is a fusion protein comprising a toxic agent, which agent is toxic to gonadotropin receptor bearing cells.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the toxic agent is selected from the group consisting of β-lactamase, γ-interferon, Fas ligand, sphingomyelinase, apoptosis promoting agents, proteases, phospholipases, and steroidogenesis inhibiting agents.

### Claim 28 (depends on 15)

The method according to claim 15, wherein an oligosaccharide in the analog is tethered to a toxic agent, which agent is toxic to gonadotropin receptor bearing cells.

### Claim 29 (depends on 15)

The method according to claim 15, wherein the analog is administered with a therapeutically effective amount of an endogenous gonadotropin secretion suppressing agent.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the suppressing agent is an estrogenic compound.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the suppressing agent is an GnRH agonist.
